Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Micronised Progesterone · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Crinone 8% group | EXPERIMENTAL | Female subjects undergoing IVF/ET treated with Crinone 8% intravaginally |
| Intramuscular progesterone group | ACTIVE_COMPARATOR | Female subjects undergoing IVF/ET treated with 60 mg progesterone intramuscularly once daily |
| Name | Type | Description |
|---|---|---|
| Micronised Progesterone | DRUG | Micronised progesterone administered intravaginally once daily from the day of ET. If pregnancy was confirmed on day 14 of progesterone administration, progesterone was continued for another 45 days. |
| Progesterone | DRUG | Progesterone 60 mg administered intramuscular once daily from the day of ET. If pregnancy was confirmed on day 14 of progesterone administration, progesterone was continued for another 45 days. |
Inclusion Criteria: * Patient has given written informed consent * BMI \< 25 kg/m2 * Age \< 36 years * \<3 prior ART cycles (IVF, ICSI and related procedures) * Infertility * Regular spontaneous ovulatory menstrual cycles Exclusion Criteria: * Habitual abortion * Hydrosalpinges * History of past ...
Micronised Progesterone is used for infertility, specifically as luteal phase support in women undergoing in vitro fertilisation (IVF) and embryo transfer (ET). It is a small molecule being developed by Merck & Company, Inc. (MRK) and is currently in Phase 3 clinical development.
Micronised Progesterone is being developed by Merck & Company, Inc., which trades under the ticker MRK. The company is conducting clinical trials to evaluate the drug's use in infertility treatment.
Micronised Progesterone is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 3 trial has been completed, with a total enrollment of 238 participants.
Micronised Progesterone has one completed Phase 3 trial, identified as NCT01081652. The study evaluated the drug (Crinone 8%) for luteal phase support in women undergoing IVF and embryo transfer in China. The trial enrolled 238 female participants and was actively controlled.
Yes, Micronised Progesterone is also known as Crinone 8%. The Phase 3 clinical trial NCT01081652 used the brand name Crinone 8% to refer to the drug being studied for luteal phase support in infertility treatment.